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Objectives: The present analysis included patientswithmyocardial infarction from the SCAR registry inArgentina.
It reports how health insurance coverage inﬂuenced the outcomes.
Methods: Eighty-seven centers participated in a cross-sectional nation-wide multicenter survey.
Results: Seven hundred and ﬁfty-eight patients were included, 476 (60.55%) with STEMI and 281(39.45%) non-
STEMI (NSTEMI).
In-hospital mortality was 7.35%. Mortality was independently associated with age (OR 1.06, CI95 1.02–1.1,
p = 0.001), left ventricular dysfunction (OR 7.12, CI95 2.5–20, p b 0.001), and Killip 3–4 (OR 4.86, CI95 1.64–14,
p = 0.004). Treatment with ACEi (OR 0.18, CI95 0.06–0.48, p b 0.005) and beta-blockers (OR 0.22, CI95 0.07–0.62,
p = 0.05) was associated with lower mortality.
In STEMI, themean time from symptomonset to admissionwas 120min (60–330) for patients arriving fromhome,
and 240 min (120–510) for patients referred from other institutions. 285 patients underwent PCI with mean
door-to-balloon time of 107 min (60–231); 92 patients received thrombolysis (mean door-to-needle time of
55 min (29–90)).
Mortality in STEMI was 8%, which was independently associated with age (OR 1.09, CI95 1.04–1.14, p b 0.001),
Killip 3–4 (OR 3, CI95 1.24–12.8, p = 0.02), and inotrope requirement (OR 19, CI95 6–60, p b 0.001).
Door-to-balloon time b90 min for primary PCI was independently associated with a signiﬁcant reduction
in mortality (OR 0.11, CI0.01–0.68, p = 0.001) in STEMI.
We observed signiﬁcant differences in the rate of PPCI and time to reperfusion according to the insurance
coverage that might have inﬂuenced the outcomes.
Conclusions:Outcomes in AMIwere affected by insurance coverage. Efforts to improve reperfusion rates and
delay to treatment are necessary.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Coronary artery disease remains a major public health problem in
Latin America, especially in Argentina [1]. The GRACE has shown
worse outcomes among Latin American patients with acute myocardial
infarction (AMI) compared with European and American patients [2].
Data from international registries may not be representative of the pa-
tient population in Argentina due to differing characteristics and health
policies.
Insurance coverage may affect mortality and clinical outcomes in
patients with AMI [3]. Little information is available on the potential of
insurance systems to reduce inequalities in the treatment and outcomes
of acute coronary syndromes.nd Ltd. This is an open access article uThe present report is a prespeciﬁed sub-analysis of patients with AMI
from the global SCAR (Síndrome Coronario Agudo en Argentina) registry
that included all ACS (myocardial infarction and unstable angina),
performed to evaluate patient characteristics, procedural details and in-
hospital outcomes. The present analysis reports how health insurance
coverage inﬂuenced treatment and outcomes in Argentina.
2. Material and methods
The SCAR registry was conducted by the research area and the
Cardiovascular Emergency Council of the Argentine Society of
Cardiology (SAC). It was a cross-sectional nation-wide multicenter
survey developed in Argentina. Data from patients were uploaded to a
web site.
Cardiologists who participated in the registry were advised not to
modify any therapeutic strategies and treatment was left to the discre-
tion of the physician.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Demographic characteristics.
MI (all) STEMI
Age (median ± SD) 61.9 ± 12.4 61 ± 12.3
Male (%) 76.6 75
BMI (median ± SD) 27.9 ± 4.62 27.9 ± 4.62
Diabetes (%) 22.2 20
DBT on insulin (%) 14 11
Current smoker (%) 37.7 42
Former smoker (%) 24.1 22
Hypercholesterolemia (%) 43.3 51
Hypertension (%) 66.7 63
Chronic stable angina (%) 8.4 7
Myocardial infarction (%) 18.3 13
Percutaneous angioplasty (%) 14.7 10
CABG (%) 5.12 2
Heart failure (%) 5.25 3
Chronic pulmonary disease (%) 6.32 6.11
Unstable angina (%) 9.17 5
Stroke (%) 2.9 3
HIV (%) 2.11 1.3
Neoplasm (%) 4 2.9
Coronary obstruction N50% (%) 25 18%
Chronic renal failure (%) 3.78 2.36
Peptic ulcer (%) 2.86 3.24
Bleeding (%) 2.71 2.14
ASA/clopidogrel (%) 36 29
ACE/ARA II 41 39.3
Statins (%) 23.6 18
Beta-blockers (%) 31.6 25.2
Health insurance coverage (%)
–Uninsured 17 20
–OS 56 56
–Private insurance 27 24
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Argentine laws and Argentine data protection laws. No individual
speciﬁc consent forms for the study were obtained. The protocol was
reviewed and approved by an independent ethics committee and ap-
proved by internal committees in each institution.
The patients included in the analysis had a diagnosis of AMI with at
least two of the following inclusion criteria: symptoms of myocardial
ischemia for N20 min, ST segment changes or T wave inversion in two
leads compatible with myocardial ischemia, or new left bundle branch
block, or development of new abnormal Qwaves, elevation of troponins
or CK-MB.
ST-segment elevation myocardial infarction (STEMI) was diagnosed
when ST-segment elevation ≥1 mm was observed in at least two
contiguous leads in EKG, or when a new left bundle branch block or
new abnormal Q waves developed.
Patients with MI N24 h, secondary angina and patients without typi-
cal angina were excluded for the present analysis.
Every medical institution afﬁliated to SAC was invited to participate
in the registry through a mail letter. Eighty-seven centers in Argentina
(academic institutions, community hospitals and private hospitals)
agreed to participate. Fifty ﬁve percent of the participating centers had
a Cardiology Fellow Program, 77% had a Cardiac Catheterization
Laboratory for Primary Angioplasty (PCI) available 24 h a day, 7 days a
week; and 74% had a Cardiovascular Surgery Service.
Patients were consecutively recruited from intensive care units
(ICU) or cardiology departments. The centers were incorporated to
the registry in different periods, between March and October 2011,
and everyone included patients during a threemonth period. A comput-
erized case record form (CRF)was ﬁlled-in for each eligible patient, and
data was recorded on-line. In the case of missing data, an investigator
from the SAC contacted the local investigator to obtain any missing
information.
The following data were collected: cardiovascular and non-
cardiovascular medical history, cardiovascular risk factors, clinical
progression including symptoms on admission and Killip–Kimball class,
therapeutic management, laboratory tests and in-hospital outcomes.
Health insurance data was recorded: it included private insurance,
“obras sociales” (OS) which are organizations that manage health cover-
age for people who are still working or retired, and uninsured people,
who depend on health assistance at public hospitals.
2.1. Statistical analyses
For quantitative variables, means, standard deviations, interquartile
range (IQR), as well asminimumandmaximum valueswere calculated.
Discrete variables were presented as percentages. Comparisons were
made with chi-square or Fisher's exact tests for discrete variables, and
by unpaired T test, Mann–Whitney U test or Wilcoxon signed-rank
test for continuous variables.
There are no ofﬁcial data about the incidence of myocardial infarc-
tion in Argentina. Considering the 2010 census with 40.117.096 resi-
dents in Argentina [4] and estimating 10/10.000 the incidence of MI
from previous studies, we calculated 800 cases, with alpha error of 0.05.
Multiple logistic regression analyses were performed for predictors
of in-hospital outcomes. Variables included in the ﬁnal multivariate
models compromised thosewith a signiﬁcance level b0.01 n the univar-
iate analyses, unless otherwise stated. A statistical analysis was
performed with STATA 9.0 (STATA Corporation, College Station, TX®).
3. Results
Seven hundred and ﬁfty-eight patients were included, 476 (60.55%)
with STEMI and 281(39.45%) non-STEMI. Demographics for the popula-
tion are shown in Table 1.
Most patients (72.8%) arrived from their home, and 27.2% were
referred from other hospitals for the following reasons: Hospitalcomplexity (16%), insurance coverage (3.95%), medical decision
(2.24%), family decision (1.31%), other (1.03%). Although the median
time from symptom onset to admission was 135 min (60–345), there
was a mean delay of 242 min (120–510) when patients were referred
from other institution.
Angina 24 h before the admission was present in 30.7% of patients,
and the majority (80.7%) were on Killip class I on admission, while 8%
were on Killip 3/4.
Sixty three percent received anticoagulation therapy, 99% non-
STEMI and 36% STEMI (low molecular weight heparin in 58% of
patients), for an average of three days (2–5 days). Ninety nine percent
of patients were treated with aspirin, 86% with clopidogrel and 11%
with prasugrel. Antiaggregation therapy was started in the ICU in 55%
of patients, in the emergency department in 27%, immediately before
PCI in 12%, and after PCI in 6%. The median loading dose of clopidogrel
was 300 mg (IR 300–600) and the maintenance dose 75 mg Q.D.
The mean hospital stay was 5 days (4.5–7) and mean ICU stay was
4 days [3–5].
In-hospital mortality was 7.35%, 85% due to cardiac complications.
The variables associated with mortality are shown in Table 2.
In a multivariate model, mortality was independently associated
with age (OR 1.06, CI95 1.02–1.1, p = 0.001), moderate or severe left
ventricular dysfunction (OR 7.12, CI95 2.5–20, p b 0.001), Killip 3–4
(OR 4.86, CI95 1.64–14,p = 0.004). Treatment with ACEi (OR 0.18, CI95
0.06–0.48, p b 0.005) and beta-blockers (OR 0.22, CI95 0.07–0.62,
p = 0.05) were independently associated with lower in-hospital
mortality.
STEMIwas observed in 476 patients on admission. The demographic
characteristics for these patients are shown in Table 1. Compared to
non-STEMI, patients with STEMI were younger (p = 0.01), and prior
hospitalization for UA or HF was more frequent in NSTEMI than in
STEMI patients (15% vs. 5.6% for UA, p = 0.013; and 9 vs. 3%, for HF
p = 0.01, respectively).
Table 2
Univariate analysis for mortality in MI.
OR (CI) p
Age 1.07 (1.05–1.1) b0.001
Female 1.86 (1.03–3.3) 0.04
DBT 2.22 (1.24–3.98) 0.007
TBQ 0.47 (0.24–0.9) 0.024
DLP 0.9 (0.5–1.62) 0.72
HTA 2.23 (1.1–4.5) 0.026
CSA 1.84 (0.79–4.3) 0.16
UA 1.45 (0.59–3.56) 0.41
HF 5.82 (2.64–12.84) b0.001
LBBB 2.83 (1.12–7.17) 0.028
RBBB 3.98 (1.79–8.86) 0.001
CRF 3.79 (1.47–9.81) 0.006
Specular ST changes 2.6 (1.22–3.83) 0.009
ST elevation 1.36 (0.74–2.49) 0.32
SAP 0.98 (0.96–0.99) b0.001
DAP 0.95 (0.93–0.97) b0.001
KK 3.24 (2.5–4.2) b0.001
Right ventricular dysfunction 8.6 (3.7–19.7) b0.001
Glycemia on arrival 1.01 (1.003–1.09) b0.001
Fasting glycemia 1.01 (1.01–1.02) b0.001
Coronary angioplasty 0.59 (0.31–1.11) 0.1
Clopidogrel 0.70 (0.34–1.44) 0.33
Beta-blockers 0.06 (0.03–0.12) b0.001
Statins 0.09 (0.04–0.19) b0.001
ARE 0.1 (0.05–0.19) b0.001
Acute renal failure 6.82 (3.3–14) b0.01
Stroke 4.28 (1.14–16.1) 0.031
Major bleeding 2.15 (0.62–7.52) 0.23
Hypotension 12.26 (5.85–25.66) b0.001
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(60–330) for patients arriving from home, and 240 min (120–510)
for patients referred from another institutions.
285 patients underwent primary PCI with mean door-to-balloon
time of 107 min (60–231) min; 92 patients received thrombolysis
with mean time from symptom onset to admission 180 min (110–
250), mean door-to-needle time 55 min (29–90); 29 patients were
treated with rescue PCI, 16 p with pharmacoinvasive-PCI and 2 by
facilitated-PCI. The reasons for no reperfusion were: late presentation
(34%), non-STEMI (29%), contraindication (1.5%), transitory ST eleva-
tion (12%), not reported (13%), others (10.5%).
Mortality (8%) was associated with time to reperfusion: door-to-
balloon time less than 90min for primary PCI was associatedwith a sig-
niﬁcant reduction in mortality ((OR 0.34, CI95 0.11–0.98), p = 0.04).
Twenty patients (2.6%) presented bleeding complications including
12 (60%) upper GI bleeding, 3 (15%) intracranial bleeding, 2 (10%)Table 3
Differences in outcomes and procedures in patients with different insurance coverage.
Uninsured
(17%)
OS
(55.8%)
Hospital mortality 6.3% 9.5%
Coronary angiography 35.8% 47%
Coronary angioplasty (total) 25.8% 39.7%
Coronary angioplasty in non-STEMI 27.3% 54.8%
Reperfusion in STEMI 76.3% 79.7%
Primary angioplasty 56.3% 75.5%
Hospital mortality in STEMI 4.3% 11.5%epistaxis, 1 (5%) lower GI bleeding, 1(5%) hematuria, and 1(5%)
hemoptysis.
Medication prescribed at discharged was aspirin in 99% of patients,
dual antiplatelet therapy in 87%, ACEi in 81%, beta-blockers in 89% and
statins in 95%.
For every year over 65 years of age there was a 7% increase in
mortality, females had almost twice the risk for mortality than males
(OR 1.86(1.03–3.33)), and a history of diabetes (OR 2.2 (1.2–4)) and
hypertension were associated to in-hospital death in a univariate anal-
ysis. Mortality was independently associated with age (OR 1.09, CI95
1.04–1.14, p b 0.001), Killip 3–4 (OR 3, CI95 1.24–12.8, p = 0.02), and
inotrope requirement (OR 19, CI95 6–60, p b 0.001). Door-to-balloon
time b 90 min for primary PCI (PPCI) was independently associated
with a signiﬁcant reduction in mortality (OR 0.11, CI0.01–0.68,
p = 0.001) in STEMI.
Fifty-six per cent had OS, 27% had private insurance and 17% were
uninsured patients. There were demographic differences between
groups: patients with OS were older (62.9 ± 12 year) than uninsured
patients (57.4 ± 8 year) and patients with private insurance (60 ±
14 year), more patients were ≥75 years old (21%, 3.2%,14.7% respec-
tively), ANOVA 0.002 (p b 0.001 between OS and uninsured patients
p = 0.07 between uninsured patients and patients with private insur-
ance). Compared to uninsured patients and patients with private insur-
ance, patients with OS had more diabetes (25% vs. 17% vs. 10%,
respectively, ANOVA 0.004, p = 0.004 between OS and private insur-
ance) and arterial hypertension (ANOVA 0.0008 (p = 0.002 between
OS and uninsured patients and p = 0.03 between patients with private
insurance and uninsured patients)).
Patients with OS had higher mortality. Patients with private insur-
ance were treated with more invasive procedures(Table 3 and Fig. 1).
4. Discussion
The SCAR registry observed a 7.35% overall mortality for AMI and 8%
for STEMI in Argentina, higher than the mortality described in Europe
[5], the US [6] and developing countries [7]. The outcomeswere affected
by insurance coverage.
Baseline characteristics of the population did not differ signiﬁcantly
from other registries. We studied a younger population, and age is a
strong predictor of mortality in acute coronary syndromes (ACS) [8].
Nevertheless, patients with OS were signiﬁcantly older and had more
diabetes, two conditions associated with mortality.
Ventricular dysfunction and hemodynamic instability have been as-
sociated with mortality in many other trials, and beta-blockers have
demonstrated a reduction in mortality, reinfarction and sudden death
afterMIwhen they are appropriately prescribed in hemodynamic stabi-
lized patients [9,10]. More than 80% of patients in the SCAR registryPrivate
(26.8%)
p
2.6% ANOVA 0.0089
(*between OS and private p = 0.007)
58% ANOVA 0.0006 (*p b 0.001 between uninsured
and private; p = 0.046 between OS and private)
47.1% ANOVA 0.039
(p = 0.048 between uninsured and OS;
p = 0.003 between uninsured and private)
68.5% 0.002 (p = 0.044 between uninsured and OS;
p = 0.002 between uninsured and private)
84.2% ANOVA 0.18
92.6% ANOVA b 0.001 (p = 0.002 between uninsured
and OS, p = 0.03 between OS and
private, p b 0.001 between uninsured and private)
2.8% 0.0089 (p = 0 between OS and private)
Fig. 1. Outcomes and procedures according to insurance coverage.
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of patients at discharge.
So, how can we explain the higher mortality observed in SCAR?
Patient proﬁle alone does not seem to explain differences in short-
term clinical outcomes after MI [2,7,11,12]. The variation in rates of re-
perfusion therapies, and the delay in initiating speciﬁc treatments and
socioeconomic variablesmight play a role. Many reports have described
geographic variations in treatment patterns that could be related to out-
comes [13,14]. Acute reperfusion therapywith either PPCI or ﬁbrinolysis
reduces mortality in eligible patients in STEMI [15]. Rates of reperfusion
are improving in Europe [16] and the USA [6], but it is heterogeneous in
other registries. In France, the overall rate of cardiovascular mortality
among patients with STEMI decreased with the greater use of reperfu-
sion therapy between 1995 and 2012 [17].
In the SCAR registry 79% of the patients received reperfusion therapy
in STEMI (60% went to PPCI and 24% went to thrombolysis), compared
to 64% and 14%, respectively, in the French registry [18]. We observed
signiﬁcant differences in the rate of PPCI and time to reperfusion accord-
ing to insurance coverage.
The use of reperfusion therapy was not independently associated
with mortality in the regression analysis, nevertheless, time to PPCI
b90 min correlated to less mortality in STEMI, as it has been demon-
strated in prior trials [19,20]. Although there is evidence that treatment
delay is harmful for both PPCI and FL [21], SCAR did not ﬁnd door-to-
needle to be a signiﬁcant predictor of mortality in a multivariate analy-
sis. This can be related to the low number of patients included in this
group.
However, the relative mortality beneﬁt of PPCI over FL depends not
only on hospital-based PCI-related delay, but also on patient character-
istics and system delay (eg. location, weather and trafﬁc) [22]. For
example, differences in care-seeking behavior may be caused by
cultural factors reﬂecting differences in interpretation of the signs and
symptoms of acute coronary disease [23]. In the acute stage of MI, the
use of invasive procedures could be related to the type of payer [24].
Nearly 30% of patients were referred from other hospitals in SCAR,
with a longer delay to initiate treatment. We have no information, but
it is possible that the choice of transfer destination might have been
driven by the presence of supplemental insurance or corporate relation-
ships between hospitals that refer and admit patients despite the
potential beneﬁt associated with transfer, as has been demonstrated
previously by Iwashyna in Pennsylvania [25]. Even among patientswho do not require transfer for reperfusion, a substantial proportion
often suffers needless delays from door to FL or PCI. Prior studies have
shown that many patients who are transferred from hospitals without
PCI capability to a PCI-capability institution experience long delays in
treatment without a clear survival beneﬁt [26–28]. In Argentina OSs
have their own clinics or economic arrangements with private clinics
where patients are usually transferred to receive speciﬁc treatments
like coronary angioplasty. This could have resulted in long delays.
It is important to consider other factors.Wang et al. described disso-
ciation between door-to-balloon time improvement and decrease in
mortality, highlighting the importance of overall quality of care
improvement for AMI [29]. It could be possible that single processmea-
sures are simple reﬂections of the entire care system organization and
cultural and socioeconomic situation. No visible differences could
contribute to the results, like equipment, personal training or type of
stents used. In 2000, French laws extended the system of health
coverage and designed a free full universal medical coverage insurance
for low-income patients b60 years of age. In this system, patients were
admitted to the same types of institutions, including academic hospitals
and private clinics and the use of cardiac catheterization and coronary
interventions was similar. Probably that was the reason why in-
hospital mortality was also comparable. This should alert as to the
translation of results between different countries around the word.
5. Limitations
Themethods used to collect data for SCAR are subject to a number of
recognized limitations thatmay hinder its ability to generalize the study
ﬁndings to the entire country. Restriction of the registry to patients who
were admitted may have resulted in the exclusion of patients dying
early in the emergency room. Otherwise, it is a voluntary registry; as a
result our survey included a high proportion of academic medical cen-
ters with revascularization facilities.
However, SCAR is the largest multicenter registry to include the
complete spectrum of patients with ACS in Argentina.
6. Conclusions
Despite that mortality has decreased since 2005 [30], the SCAR reg-
istry shows that in-hospital mortality for AMI persists to be high in
Argentina. Efforts to improve reperfusion rates and delay to treatment
22 H.C. Arazi et al. / IJC Metabolic & Endocrine 4 (2014) 18–22are necessary, especially in STEMI. However we must consider other
variables that might inﬂuence the mortality like care system organiza-
tion and cultural and socioeconomic situation. Universal medical cover-
age doesn't seem to eliminate health inequalitieswhen providing access
to optimal care is not guaranteed. Coordinated intersectorial actions
should be taken to ensure greater access to the best treatment in AMI.
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